Recently Featured

Asahi Kasei acquires German company Aicuris

April 30, 2026
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company specializing in innovative therapies for infectious diseases. This strategic move enhances Asahi Kasei’s portfolio, positioning the company to leverage Aicuris’ expertise in anti-infective treatments, which is increasingly critical in a landscape marked by rising antibiotic resistance and the need for novel…

Trump Executive Order Accelerates Psychedelics Biotech Sector

April 30, 2026
Meant to speed research and access to psychedelics for mental health conditions, the recent executive order from former President Trump marks a significant shift in the regulatory landscape for psychedelics. This order is part of a broader trend that has been gaining momentum, as regulatory bodies increasingly recognize the potential of psychedelics in treating various…

CleanAssure Launched as an ISO Class 5 Controlled Cleanroom for Sterile Single-Use Assemblies

April 29, 2026
Freudenberg Medical, a Kaiserslautern, Germany-based contract design manufacturing partner, has launched CleanAssure, a new ISO Class 5 controlled cleanroom aimed at delivering clean and sterile single-use assemblies for biopharmaceutical customers. This initiative comes as the biopharmaceutical industry increasingly adopts single-use systems, which necessitate stringent cleanliness and sterility standards. Freudenberg Medical specializes in manufacturing silicone and…

CRISPR Screens Reveal Human T‑Cell Genes Influencing HIV Infection

April 29, 2026
A groundbreaking study from Gladstone Institutes and the University of California, San Francisco (UCSF) has unveiled the first genome-wide map of human genes that either promote or inhibit HIV infection in primary human CD4+ T cells. Published in Cell, this research addresses a critical gap in HIV studies, which have largely relied on immortalized cell…

Ongoing Cases